Volume 154, Issue 8, Pages e8 (June 2018)

Slides:



Advertisements
Similar presentations
Volume 150, Issue 2, Pages e6 (February 2016)
Advertisements

Safety and Effectiveness of Direct-Acting Antiviral Agents for Treatment of Patients With Chronic Hepatitis C Virus Infection and Cirrhosis  Raoel Maan,
Volume 149, Issue 6, Pages (November 2015)
Clinical outcome after SVR: Veterans Affairs
Pathogenesis and Treatment of Hepatitis E Virus Infection
Donald R. VanDevanter, David J. Pasta, Michael W. Konstan 
Volume 148, Issue 1, Pages e1 (January 2015)
Arpan Mohanty, Sebhat Erqou, Kathleen A
Volume 139, Issue 5, Pages e1 (November 2010)
Volume 133, Issue 2, Pages (August 2007)
Magnitude and Kinetics of Decrease in Liver Stiffness After Antiviral Therapy in Patients With Chronic Hepatitis C: A Systematic Review and Meta-analysis 
Volume 131, Issue 2, Pages (August 2006)
Pathogenesis and Treatment of Hepatitis E Virus Infection
Volume 147, Issue 6, Pages e3 (December 2014)
Cost-Effectiveness of Access Expansion to Treatment of Hepatitis C Virus Infection Through Primary Care Providers  Thilo Rattay, Ian P. Dumont, Hauke.
Volume 149, Issue 6, Pages (November 2015)
Fasting Blood Ammonia Predicts Risk and Frequency of Hepatic Encephalopathy Episodes in Patients With Cirrhosis  John M. Vierling, Masoud Mokhtarani,
Effectiveness of Hepatitis B Treatment in Clinical Practice
Volume 153, Issue 4, Pages (October 2017)
Outcomes Among Living Liver Donors
Volume 140, Issue 7, Pages (June 2011)
A Sustained Viral Response Is Associated With Reduced Liver-Related Morbidity and Mortality in Patients With Hepatitis C Virus  Amit G. Singal, Michael.
Liver Cirrhosis Is Associated With Venous Thromboembolism Among Hospitalized Patients in a Nationwide US Study  Harry Wu, Geoffrey C. Nguyen  Clinical.
Volume 137, Issue 5, Pages (November 2009)
Volume 155, Issue 2, Pages e17 (August 2018)
Volume 135, Issue 4, Pages (October 2008)
Fasiha Kanwal, MD, MSHS, Hashem B. El-Serag, MD, MPH 
Volume 150, Issue 4, Pages (April 2016)
Accuracy of the ALFSG Index as a Triage Marker in Acute Liver Failure
Volume 154, Issue 4, Pages (March 2018)
TLL1 rs Increases the Risk of Fibrosis Progression in Caucasian Patients With Chronic Hepatitis C  Miya John, Mayada Metwally  Gastroenterology 
Volume 137, Issue 2, Pages (August 2009)
Volume 155, Issue 5, Pages e2 (November 2018)
Jean-Michel Pawlotsky  Gastroenterology 
Etiologies and Outcomes of Acute Liver Failure in Germany
Volume 153, Issue 2, Pages e17 (August 2017)
Volume 134, Issue 4, Pages e8 (April 2008)
Volume 152, Issue 5, Pages e1 (April 2017)
A. Sidney Barritt, Michael W. Fried  Gastroenterology 
Volume 141, Issue 4, Pages e3 (October 2011)
Alan J. Wigg, Rosemary McCormick, Rachel Wundke, Richard J. Woodman 
Validation of Hepascore, Compared With Simple Indices of Fibrosis, in Patients With Chronic Hepatitis C Virus Infection in United States  Laren Becker,
Patient-Reported Outcomes Following Treatment of Chronic Hepatitis C Virus Infection With Sofosbuvir and Velpatasvir, With or Without Voxilaprevir  Zobair.
Impact of New Hepatitis C Treatments in Different Regions of the World
Volume 147, Issue 6, Pages e5 (December 2014)
Histologic Predictors of Fibrosis Progression in Liver Allografts in Patients With Hepatitis C Virus Infection  Zina Meriden, Kimberly A. Forde, Theresa.
Hepatic Vein Pressure Gradient Reduction and Prevention of Variceal Bleeding in Cirrhosis: A Systematic Review  Gennaro D’Amico, Juan Carlos Garcia-Pagan,
Volume 133, Issue 2, Pages (August 2007)
Levels of Alanine Aminotransferase Confound Use of Transient Elastography to Diagnose Fibrosis in Patients With Chronic Hepatitis C Virus Infection  Elliot.
Eric S. Orman, Marwan Ghabril, Naga Chalasani 
Volume 140, Issue 7, Pages (June 2011)
Volume 133, Issue 2, Pages (August 2007)
Correlation of FIBROSpect II With Histologic and Morphometric Evaluation of Liver Fibrosis in Chronic Hepatitis C  Keyur Patel, David R. Nelson, Don C.
Volume 138, Issue 2, Pages e6 (February 2010)
Outcomes of Patients With Hepatitis B Who Developed Antiviral Resistance While on the Liver Transplant Waiting List  Melissa K. Osborn, Steven H. Han,
Pathogenesis and Treatment of Hepatitis E Virus Infection
Elizabeth Mileti, Philip Rosenthal, Marion G. Peters 
Correlation Between the Crohn's Disease Activity and Harvey–Bradshaw Indices in Assessing Crohn's Disease Severity  Severine Vermeire, Stefan Schreiber,
Volume 141, Issue 4, Pages (October 2011)
Alessio Aghemo, Maria Francesca Donato  Gastroenterology 
Volume 142, Issue 6, Pages e4 (May 2012)
Volume 156, Issue 6, Pages e12 (May 2019)
Volume 139, Issue 6, Pages e1 (December 2010)
Volume 156, Issue 5, Pages e3 (April 2019)
Volume 152, Issue 5, Pages e1 (April 2017)
Controversies in Liver Transplantation for Hepatitis C
Volume 135, Issue 5, Pages (November 2008)
Volume 148, Issue 1, Pages (January 2015)
Sanjay K. Murthy, E. Jenny Heathcote, Geoffrey C. Nguyen 
Fasiha Kanwal, Tuyen Hoang, Timothy Chrusciel, Jennifer R
Presentation transcript:

Volume 154, Issue 8, Pages 2111-2121.e8 (June 2018) Baseline Factors Associated With Improvements in Decompensated Cirrhosis After Direct-Acting Antiviral Therapy for Hepatitis C Virus Infection  Omar El-Sherif, Z. Gordon Jiang, Elliot B. Tapper, K.C. Huang, Alex Zhong, Anu Osinusi, Michael Charlton, Michael Manns, Nezam H. Afdhal, Kenneth Mukamal, John McHutchison, Diana M. Brainard, Norah Terrault, Michael P. Curry  Gastroenterology  Volume 154, Issue 8, Pages 2111-2121.e8 (June 2018) DOI: 10.1053/j.gastro.2018.03.022 Copyright © 2018 AGA Institute Terms and Conditions

Gastroenterology 2018 154, 2111-2121. e8DOI: (10. 1053/j. gastro. 2018 Copyright © 2018 AGA Institute Terms and Conditions

Figure 1 Outcome of DAA treatment among patients with CPT B and C cirrhosis. (A) Change in CPT class from baseline to week 36 from the start of DAA therapy. (B) Kaplan–Meier curves of achieving a CPT A status were plotted for those with or without SVR12 in black and gray solid lines, respectively. Dashed lines represent 95% CI. P value calculated by Cox proportional hazard regression right-censored at 36 weeks. Gastroenterology 2018 154, 2111-2121.e8DOI: (10.1053/j.gastro.2018.03.022) Copyright © 2018 AGA Institute Terms and Conditions

Figure 2 MELD purgatory before and after DAA treatment. The MELD and CPT scores of each patients in the clinical trials were plotted before the DAA treatment (A) and at the last follow-up (B). MELD purgatory was defined as CPT B or C (score ≥7) and MELD score ≤14 (Zone 4 on the MELD/CPT plot). Each open circle represents 1 or more patient with the corresponding MELD and CPT scores. The number of observations in each zone was indicated in each quadrant. Gastroenterology 2018 154, 2111-2121.e8DOI: (10.1053/j.gastro.2018.03.022) Copyright © 2018 AGA Institute Terms and Conditions

Figure 3 Kaplan Meier curves of achieving CPT A and death/transplant with BE3A score. Kaplan-Meier curves of different BE3A categories were plotted for achieving a CPT A status (A) and death or liver transplantation (B). Dashed lines represent 95% CI. Number of observations at 0, 10, 20, and 30 weeks were shown below each panel. Gastroenterology 2018 154, 2111-2121.e8DOI: (10.1053/j.gastro.2018.03.022) Copyright © 2018 AGA Institute Terms and Conditions

Supplementary Figure 1 Impact of SVR on death and liver transplantation. Kaplan–Meier curves of death or liver transplantation were plotted for those with or without SVR12 in black and gray solid lines, respectively. Individual deaths or liver transplantation before SVR12 are included in (A), but excluded in (B). Dashed lines represent 95% CI. P value calculated by Cox proportional hazard regression right-censored at 40 weeks. Gastroenterology 2018 154, 2111-2121.e8DOI: (10.1053/j.gastro.2018.03.022) Copyright © 2018 AGA Institute Terms and Conditions

Supplementary Figure 2 Comparison of BE3A score with alternative models. The performance of the BE3A model was compared to 2 alternative modeling strategies. Model 1 used continuous variables of ALT, albumin and BMI; while Model 2 used the same binary variables as the BE3A. Model 1 and Model 2 used multivariate logistic regression in comparison to the BE3A model where a univariate 0–5 point score was used. Gastroenterology 2018 154, 2111-2121.e8DOI: (10.1053/j.gastro.2018.03.022) Copyright © 2018 AGA Institute Terms and Conditions

Supplementary Figure 3 Bootstrap validation of BE3A score and BE3A calculator. The performance of BE3A score (A) and BE3A calculator (B) in predicting achieving CPT A, and the performance of BE3A calculator in predicting death or transplantation (C) was evaluated using parametric bootstrap ROC analysis. The distribution of AUC coefficient from 100 simulations was plotted in histograms. Gastroenterology 2018 154, 2111-2121.e8DOI: (10.1053/j.gastro.2018.03.022) Copyright © 2018 AGA Institute Terms and Conditions